Abstract:Objectives:There is an urgent need to develop interventions and policies to mitigate the health effects of obesity by targeting its metabolic mediators. Adrenomedullin 2 (AM2)/intermedin (IMD) is a secreted peptide that has an important role in protecting the cardiovascular system. However, the role of AM2 in type 2 diabetes is unknown.Methods:Wild-type (WT) and aP2/AM2 transgenic (aAM2-tg) mice were fed a high-fat diet (HFD) for 8 weeks, and WT mice were treated with AM2 through mini-osmotic pumps. Indirect calorimetry, ambulatory activity and food intake, hyperinsulinemic-euglycemic clamp test, glucose and insulin tolerance tests were used for assessing insulin resistance. Rat primary adipocytes and pre-adipocyte-derived adipocytes were used for in vitro experiments. Real-time PCR and western blot were used for analyses of gene expression and protein level.Results:AM2 and receptor activity-modifying proteins expressions were significantly decreased in the adipose tissue of obese mice. AM2 treatment significantly reduced blood glucose, fasting serum insulin and free fatty acid levels, improved glucose tolerance and insulin sensitivity, and increased the glucose infusion rate during a hyperinsulinemic-euglycemic clamp test, indicating ameliorated HFD-induced insulin resistance. These effects were consistently observed in aAM2-tg mice under HFD conditions, whereas the aAM2-tg mice showed less weight gain and improved glucose tolerance and insulin sensitivity. More importantly, the aAM2-tg mice had increased oxygen consumption and CO2 production, reflecting more energy expenditure. These effects may be due to increased AMP-activated protein kinase phosphorylation and reduced peroxisome proliferator-activated receptor gamma co-activator 1α (PGC1α) acetylation, which result in interactions between PGC1α and PR domain containing 16 and then promote uncoupling protein 1 (UCP1) expression in adipocytes.Conclusions:These results indicate that endogenous AM2 might be involved in energy metabolism in adipocytes through the upregulation of UCP1 expression.

Adrenomedullin is a Novel Adipokine: Adrenomedullin in Adipocytes and Adipose Tissues

The vasoactive peptide adrenomedullin is secreted by adipocytes and inhibits lipolysis through NO-mediated beta-adrenergic agonist oxidation

The clinical relevance of adrenomedullin: a promising profile?

[Adrenomedullin in the kidney: physiology and pathophysiology]

Adrenomedullin Attenuates Inflammation in White Adipose Tissue of Obese Rats Through Receptor‐Mediated PKA Pathway

Regulation of insulin secretion and blood glucose metabolism by adrenomedullin

Regulation of production and secretion of adrenomedullin in the cardiovascular system

Adrenomedullin: Potential in physiology and pathophysiology

Bench-to-bedside pharmacology of adrenomedullin

Adrenomedullin ameliorates palmitic acid-induced insulin resistance through PI3K/Akt pathway in adipocytes

Adrenomedullin: Not Just Another Gastrointestinal Peptide

Adrenomedullin as a potential therapeutic agent for inflammatory bowel disease

Adrenomedullin: Its Role in the Cardiovascular System

Adrenomedullin: A Novel Therapeutic for the Treatment of Inflammatory Bowel Disease

Adrenomedullin in adipocyte differentiation of human mesenchymal stem cells.

Adrenomedullin and Cardiovascular Disease

Intermedin/adrenomedullin 2 polypeptide promotes adipose tissue browning and reduces high-fat diet-induced obesity and insulin resistance in mice

Adrenomedullin - new perspectives of a potent peptide hormone

Adrenomedullin and cancer

Adipokines: New Potential Therapeutic Target for Obesity and Metabolic, Rheumatic, and Cardiovascular Diseases

Adrenomedullin and the integrative physiology of fluid and electrolyte balance